SecBot SecBot
425 ·Filed Nov 5, 2026

SYBX

SYNLOGIC, INC.
NEUTRAL
Impact 4/10
Horizonmonths Processed11d 17h ago SEC0001193125-26-448753
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor the effectiveness of the S-4 registration statement and shareholder votes for the merger, as well as the IND submission for CLD-423 Phase 2b UC trial expected in Q4 2026. The Phase 1a data and new license are positive for Caldera's pipeline but do not change the near-term deal timeline.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$0.5600
T+0 close · Nov 5, 2026 · via day close
Latest settled
0.00%
T+5 · $0.5600
Vs SPY
−3.29%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $0.5600entry
  2. T+1 · 11d ago 0.00%α −0.31% · $0.5600
  3. T+5 · 5d ago 0.00%α −3.29% · $0.5600
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Caldera Therapeutics, the private biotech merging with Synlogic (SYBX), announced positive Phase 1a data for its lead bispecific antibody CLD-423 and an exclusive worldwide license for a preclinical IL-17 x TL1A bispecific program from Qyuns Therapeutics. The data support planned Phase 2 trials in ulcerative colitis and Crohn's disease starting in early 2027, and the license expands Caldera's pipeline. The filing is a routine M&A communication that adds no new financial terms or changes to the pending all-stock merger and concurrent $278 million private placement.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Caldera reported Phase 1a data for CLD-423 (IL-23p19 x TL1A bispecific) showing favorable tolerability, no dose-limiting toxicities, prolonged half-life (>40 days IV), and sustained TL1A target engagement.
  • Phase 2b UC trial and Phase 2a CD trial planned to start in early 2027, with data readouts expected between late 2027 and end of 2028.
  • Caldera entered an exclusive worldwide license with Qyuns Therapeutics for a preclinical IL-17 x TL1A bispecific antibody program.
  • The all-stock merger with Synlogic and concurrent private placement of ~$278 million remain on track for early 2027 closing.
  • No changes to deal terms, timeline, or financial structure were disclosed in this filing.

Financial Impact

No new financial figures; the concurrent private placement remains at approximately $278 million in gross proceeds.

Risk Factors

  • Phase 2 clinical trials may fail to replicate Phase 1a safety/efficacy results.
  • Merger and private placement remain subject to shareholder approvals and customary closing conditions.
  • Immunogenicity data showed anti-drug antibodies in 8 of 42 subjects, though titers were low and no safety findings were attributed.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-448753
Document: 0001193125-26-448753-index-headers.html0001193125-26-448753
Document: 0001193125-26-448753-index.html0001193125-26-448753
Document: 0001193125-26-448753.txt0001193125-26-448753

Track record

5 reports on SYBX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 425 Neutral 4/10 Viewing Entry $0.5600 Now $1.10 +96.43% settles Feb 3
  2. Nov 2, 202614d ago 425 Neutral 3/10 Entry $0.5600 Now $1.10 +96.43% settles Jan 29
  3. Jul 29, 202615w ago 425 / 8-K Bearish 7/10 Entry $1.12 to $1.08 Now $1.10 +1.79% ▲ +3.57% +9.82% vs SPY
  4. May 18, 202626w ago 25-NSE Bearish 7/10 Entry $0.6600 to $1.21 Now $1.10 −66.67% ▼ −82.58% −77.72% vs SPY
  5. Apr 30, 202628w ago 10-K/A Neutral 2/10 Entry $0.6050 to $0.7150 Now $1.10 +81.82% ▲ +18.18% +15.11% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026